医学
酒精间隔消融
心脏病学
内科学
射血分数
心力衰竭
临床终点
房室传导阻滞
烧蚀
不利影响
心脏病
队列
梗阻性肥厚性心肌病
肥厚性心肌病
梗阻性心肌病
前瞻性队列研究
心肌病
射频消融术
心室流出道
队列研究
扩张型心肌病
代理终结点
心间隔
心房颤动
作者
Jan Koelemen,K Becht,Christoph Reich,Ali Amr,Elham Kayvanpour,Steffen Roßkopf,Norbert Frey,Benjamin Meder,Farbod Sedaghat‐Hamedani
标识
DOI:10.64898/2026.08.18.26360764
摘要
Background Obstructive hypertrophic cardiomyopathy (oHCM) causes substantial symptom burden and impaired functional capacity. Mavacamten has emerged as a targeted pharmacologic treatment, whereas alcohol septal ablation (ASA) is an established septal reduction therapy (SRT). Direct comparative real-world data remain limited. Methods In this propensity-controlled observational study, longitudinal registry data from Heidelberg University Hospital were analyzed. Consecutive adults with oHCM, NYHA class ≥II symptoms, and a maximum LVOT gradient ≥50 mmHg treated with mavacamten or ASA were included. The cohort comprised 107 ASA- and 113 mavacamten-treated patients. Follow-up was performed at 6 and 12 months. The primary endpoint was a composite adverse clinical outcome including cardiovascular death, heart failure hospitalization, SRT, heart transplantation, ventricular assist device implantation, permanent pacemaker implantation for third-degree atrioventricular block, or decline in left ventricular ejection fraction to <40%. Results Both treatments showed significant improvement in NYHA class and LVOT gradient reduction over 12 months. Mean LVOT gradient decreased from 100.3 to 44.2 mmHg after ASA and from 85.7 to 18.4 mmHg with mavacamten at 12 months (both p<0.001). Between-group differences were not significant at 6 months, whereas residual LVOT gradient was lower with mavacamten at 12 months (p=0.004). NT-proBNP declined in both groups and was lower with mavacamten at both follow-up visits (both p<0.001). Third-degree atrioventricular block occurred more frequently after ASA (6.5% vs 0%, p=0.002). The composite endpoint occurred in 13 ASA-(12.1%) and 4 mavacamten-treated patients (3.5%) (p=0.003), with higher 1-year event-free survival in the mavacamten group (HR 0.19; 95%-CI 0.06-0.60; p=0.001). Conclusions In this real-world comparative study, both ASA and mavacamten improved symptoms and LVOT obstruction in oHCM. Mavacamten was associated with a more favorable short-term hemodynamic and safety profile at 12 months. Graphical abstract. Study design and principal findings of a propensity-matched single-center cohort study comparing alcohol septal ablation and mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
科研通智能强力驱动
Strongly Powered by AbleSci AI